Risks

Sleep apnea demand is tied to diagnosis and treatment adherence, so reimbursement or screening softness would slow growth versus ResMed’s more diversified respiratory peers.

Competitive pressure from Philips and low-cost device makers can intensify pricing and channel incentives, but ResMed’s brand and installed base should preserve share better than smaller peers.

A long cash conversion cycle and high inventory days can amplify working-capital swings if demand normalizes, though ResMed’s balance sheet is stronger than most medtech peers.

Regulatory and reimbursement changes in sleep-disordered breathing can affect device adoption across the category, yet ResMed’s scale and payer relationships should cushion outcomes versus niche competitors.

Opportunities

Structural growth in obstructive sleep apnea diagnosis and home-based therapy adoption supports multi-year demand, and ResMed is better positioned than most peers to capture it.

ResMed’s net cash position, strong liquidity, and high interest coverage give it more flexibility than leveraged medtech peers to invest through demand cycles and supply shocks.

The company’s broad mask-and-device ecosystem supports recurring replacement demand and cross-sell, creating steadier revenue visibility than single-product competitors.

Ongoing shift toward digital sleep management and remote patient monitoring favors ResMed’s connected platform, which is more commercially established than most direct peers.

Overall Score

ResMed combines exceptional structural demand and balance-sheet resilience with manageable competitive and reimbursement risks, leaving its forward positioning stronger than most peers.